Today's Stock News: Latest Updates on Public Companies
472 news published.
Pharma, approvals and clinical updates
AbbVie (ABBV) reported positive Phase 3 topline results for upadacitinib (RINVOQ®) in adults and adolescents with vitiligo. That outcome broadens the drug’s dermatology franchise and could meaningfully lift AbbVie’s growth profile if regulatory filings follow.
Merck (MRK) won European Commission approval for Keytruda in a new adjuvant head-and-neck indication, supporting longer-term oncology revenue. Zoetis (ZTS) also secured European marketing authorization for Portela® to treat osteoarthritis pain in cats, a commercial milestone in animal health.
BridgeBio (BBIO) posted positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 — a readout that can reshape valuation assumptions for the rare‑disease developer.
PDS Biotech (PDSB) said it will seek an expedited approval pathway for PDS0101 in HPV16‑positive head and neck cancer, a regulatory strategy that investors will watch for timeline and de‑risking implications.
Mergers, takeovers and strategic combinations
Jamf (JAMF) agreed to be taken private by Francisco Partners in a $2.2 billion buyout, removing a public growth software name from investor screens. Thermo Fisher (TMO) reaffirmed its deal to buy Clario Holdings, bolstering clinical‑trial data services; both transactions reshape sector consolidation and M&A comps.
Disney (DIS) completed a business combination between Fubo and Hulu + Live TV, creating a unique vMVPD player and signaling ongoing bundling and distribution shifts in streaming that could pressure traditional pay-TV economics.
Corporate results and guidance movers
Opera (OPRA) topped Q3 estimates and raised full‑year ranges for revenue and adjusted EBITDA, offering a near-term positive read on ad-tech monetization. Boeing (BA) released Q3 results that remain central to aerospace supply‑chain and airline capex outlooks.
United Therapeutics (UTHR) posted record Q3 results, underscoring commercial momentum for its pulmonary portfolio. Graham Holdings (GHC) also reported Q3 earnings, noteworthy to media and education investors parsing cyclical ad and subscription trends.
Tech, AI, data and infrastructure
Commvault (CVLT) launched Data Rooms to link enterprise data with AI platforms securely — a product aimed at enterprises trying to operationalize AI while managing data governance risk.
CleanSpark (CLSK) entered the Texas market with land and large-scale power assets to deploy an AI data center in Greater Houston, a strategic move tying crypto‑era infrastructure builders to demand for AI compute capacity: announcement.
Mobileye (Intel/INTC) expanded localization for ADAS in India with VVDN Technologies, while NXP (NXPI) and Magnachip (MX) rolled out chipsets and power products supporting EV and industrial electrification — incremental product steps that feed semiconductor demand narratives.
Energy, mining and climate tech moves
National Energy Services Reunited (NESR) won a multi‑billion dollar unconventional contract from Saudi Aramco, a major backlog and revenue catalyst in Mideast oilfield services: contract note.
CleanSpark (CLSK)’s Texas land and power purchase also ties into the race for low‑cost energy hubs for AI and crypto compute — investors will track permitting and grid interconnect timelines closely.
Capital markets, listings and financing
Terrestrial Energy (IMSR) began trading on the Nasdaq, marking a public listing for a nuclear/advanced‑energy company and expanding investor access to late‑stage energy technologies: filing.
Resilience secured up to $825 million in financing to accelerate CDMO expansion, while smaller capital raises and mining orders continue to circulate in crypto and energy-related names.
Defense, government and AI strategy
IBM (IBM) unveiled a defense‑focused AI model targeting mission planning and decision support, highlighting specialized AI demand from government buyers and implications for contract pipelines: product announcement.
Leonardo DRS (DRS) announced a board and CEO transition; governance moves at defense contractors often prompt investor focus on program continuity and backlog delivery: details.
Selected biotech and diagnostics developments
Caris (CAI) presented data validating TET2 clonal hematopoiesis as a biomarker for enhanced immunotherapy response, a diagnostics signal that could influence trial design and companion-diagnostic demand: note.
Cellipont and Ernexa (ERNA) entered a cell‑therapy manufacturing partnership to advance ERNA‑101 toward ovarian cancer trials, reflecting ongoing outsourcing trends in cell therapy scale‑up: release.
Retail, distribution and partnerships
Eli Lilly (LLY) launched LillyDirect with Walmart Pharmacy for retail pick‑up of Zepbound, a distribution shift that may affect patient access and competitive dynamics in obesity therapeutics: partnership note.
- Quick hits: AbbVie Phase 3 vitiligo, Fubo–Hulu combo, and CleanSpark Texas AI data center.
- Watchlist: AI productization from Commvault, the Aramco award to NESR, and regulatory paths for oncology and rare‑disease drugs at PDS Biotech.
Don't miss out on market-moving news. Bookmark this page and check back regularly for the most recent updates on stocks, sectors, and the overall market landscape. Stay informed, stay ahead, and make smarter investment choices with our comprehensive stock news coverage.
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
What You'll Find on This Page:
- Breaking financial news and market-moving headlines
- FDA approvals and clinical trial results for biotech and pharma stocks
- Stock offerings, dividends, and other corporate actions
- Mergers, acquisitions, and strategic partnerships
- Business news affecting company performance and stock prices
- Easy-to-use tags for quick news categorization
- Stock tickers for instant company identification
- AI sentiment analysis to gauge market reaction
- Estimated impact scores to assess potential stock movement